Emerging Company Profile
CatalYm: opening up tumors to immune cells
Emerging Company Profile: German start-up targets GDF15’s immunosuppressant function to enable immune cell infiltration to tumors
Berlin-based CatalYm aims to resensitize cancer cells to checkpoint inhibitors by targeting GDF15, which restores the ability of immune cells to infiltrate the tumor.
CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors.
The Munich-based biotech has raised €50 million ($58.2 million) in a series B round led by Vesalius Biocapital III